Kaplan RM, et al. - Researchers investigated whether performing direct-current cardioversion (DCCV) in obese patients on novel oral anticoagulant (NOAC) is safe. They included in this study all patients without a previous transesophageal echocardiogram (TEE) who underwent DCCV after ≥ 3 weeks of NOAC or therapeutic warfarin treatment over a 3-year period at a single center. Findings revealed that patients taking NOACs and warfarin demonstrated a low rate of stroke in all weight classes following DCCV. Data also demonstrated that even in the absence of TEE, using NOAC in severely obese patients undergoing DCCV seemed safe.